Reversal of multidrug resistance in drug-resistant human breast cancer cell line MCF-7/ADR by calmodulin antagonist O-(4-ethoxyl-butyl)-berbamine

Acta Academiae Medicinae Sinicae

Volumn 28, Issue 2, 2006, Pages 164-168

  Cheng, Yan Hong ^a   Qi, Jing ^a   Xiong, Dong Sheng ^a   Liu, Jie Wen ^a   Qi, Shu Ling ^a   Pan, Bing ^a   Yang, Chun Zheng ^a   Zhu, Hui Fang ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

O (4 ethoxyl) butyl berbamine; Calmodulin antagonist; Multidrug resistance; Reversal

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CALMODULIN INHIBITOR; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; O (4 ETHOXYL BUTYL)BERBAMINE; UNCLASSIFIED DRUG; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; BENZYLISOQUINOLINES; BREAST NEOPLASMS; CALMODULIN; CELL CYCLE; CELL LINE, TUMOR; DOXORUBICIN; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; P-GLYCOPROTEIN;

EID: 33744790294     PISSN: 1000503X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Chinese source. 1989. 210-224.
2. Xu YH, Zhang SP. A derivative of biabenzylisoquinoline alkaloid is a new and potential calmodulin antagonist. Biochem Biophys Res Commun, 1986, 140(1):461-467.
3. Liu JW, Qi SL, Zhu HF, et al. The effect of calmodulin antagonist berbamine derivative-EBB on hepatoma in vitro and in vivo. Chin Med J, 2002, 115 (5):759-762.
4. Chinese source. EBB HT1080. 2005, 27(3):311-314.
5. Chinese source. 1980, 1(2): 70-76.
6. Strobl JS, Peterson VA. Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13. J Pharmacol Exp Ther, 1992, 263 (1):186-193.
7. Lo YL, Liu FI, Yang JM, et al. Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid. Anticancer Res, 2001, 21(1A):445-450.
8. Chinese source. 1995, 17(5):347-349.
9. Woodland C, Koren G, Wainer IW, et al. Verapamil metabolites: potential P-glycoprotein-mediated multidrug resistance reversal agents. Can J Physiol Pharmacol, 2003, 81(8):800-805.
10. Qi J, Wang S, Liu G, et al. Pyronaridine, a novel modulator of P-glyoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo. Biochem Biophys Res Commun, 2004, 319 (4):1124-1131.
11. Kahl CR, Means AR. Regulation of cell cycle progression by calcium/ calmodulin-dependent pathways. Endocrine Reviews, 2003, 24 (6):719-736.
12. Lavie Y, Cao H, Volner A, et al. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporine A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem, 1997, 272(3):1682-1687.